Novartis Raises Full-Year Profit Forecast

FRANKFURT: Due to robust growth in sales of medications like Kisqali, Kesimpta, and Leqvio during the first quarter, Novartis announced an enhanced full-year earnings prediction on Tuesday.

The Swiss pharmaceutical company stated that it now anticipates its 2025 operating income, after adjustments for specific items, to increase by a “low double-digit” percentage.

Previously, the company had projected a growth rate ranging from “high single to low double-digit,” contrasting with the 22% surge observed in 2024.

Novartis to Acquire Anthos

Novartis has also agreed to acquire Anthos for a sum of up to $3.1 billion.